Abstract
COVID-19 has claimed more than 2.7 × 106 lives and resulted in over 124 × 106 infections. There is an urgent need to identify drugs that can inhibit SARS-CoV-2. We discuss innovations in computational infrastructure and methods that are accelerating and advancing drug design. Specifically, we describe several methods that integrate artificial intelligence and simulation-based approaches, and the design of computational infrastructure to support these methods at scale. We discuss their implementation, characterize their performance, and highlight science advances that these capabilities have enabled.
Funding Information
  • UK MRC Medical Bioinformatics project (MR/L016311/1)
  • United States Department of Energy (DE-SC0019323)
  • CANDLE project by the ECP (17-SC-20-SC)
  • UCL Provost
  • DOE Office of Science through National Virtual Biotechnology Laboratory
  • UKCOMES (G@EP/L00030X/1)
  • EU H2020 CompBioMed2 Centre of Excellence (823712)

This publication has 22 references indexed in Scilit: